We are live on
!
Find out more
CAM
Cormorant Asset Management Portfolio holdings
AUM
$1.95B
1-Year Est. Return
773.9%
This Fund
S&P 500
This Quarter
Est. Return
+4.81%
1 Year Est. Return
+773.9%
3 Year Est. Return
+3,976.92%
5 Year Est. Return
+17,750.67%
10 Year Est. Return
+592,782.78%
AUM
$603M
AUM Growth
-$85.4M
(-12%)
Cap. Flow
-$61M
Cap. Flow
% of AUM
-10.11%
Top 10 Holdings %
Top 10 Hldgs %
45.31%
Holding
86
New
11
Increased
4
Reduced
19
Closed
15
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
BLUE
bluebird bio
BLUE
|
+$25.6M |
| 2 |
RXDX
Ignyta, Inc.
RXDX
|
+$12.2M |
| 3 |
PTLA
Portola Pharmaceuticals, Inc.
PTLA
|
+$12M |
| 4 |
Omeros
OMER
|
+$9.6M |
| 5 |
GTHX
G1 Therapeutics, Inc. Common Stock
GTHX
|
+$8.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Theravance Biopharma
TBPH
|
+$18.3M |
| 2 |
Corbus Pharmaceuticals
CRBP
|
+$13.9M |
| 3 |
FWP
Forward Pharma A/S American Depositary Shares
FWP
|
+$12.7M |
| 4 |
ZYNE
Zynerba Pharmaceuticals, Inc
ZYNE
|
+$10.1M |
| 5 |
CBPO
China Biologic Products Holdings, Inc.
CBPO
|
+$10M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.63% |
| 2 | Miscellaneous | 0.37% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
76
Ultragenyx Pharmaceutical
RARE
$1.27B
| – | – |
-75,000
| Closed | -$5.08M |
|
77
Syndax Pharmaceuticals
SNDX
$1.58B
| – | – |
-240,403
| Closed | -$3.3M |
|
|
VIRX
78
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
| – | – |
-14,862
| Closed | -$2.13M |
|
|
ZYNE
79
DELISTED
Zynerba Pharmaceuticals, Inc
ZYNE
| – | – |
-500,000
| Closed | -$10.1M |
|
|
SYNH
80
DELISTED
Syneos Health, Inc. Class A Common Stock
SYNH
| – | – |
-200,000
| Closed | -$9.17M |
|
|
EPZM
81
DELISTED
Epizyme, Inc
EPZM
| – | – |
-140,000
| Closed | -$2.4M |
|
|
AVEO
82
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
| – | – |
-70,000
| Closed | -$413K |
|
|
FWP
83
DELISTED
Forward Pharma A/S American Depositary Shares
FWP
| – | – |
-84,168
| Closed | -$12.7M |
|
|
TIG
84
DELISTED
TiGenix American Depositary Shares
TIG
| – | – |
-129,032
| Closed | -$2.01M |
|
|
AVXS
85
DELISTED
AveXis, Inc. Common Stock
AVXS
| – | – |
-30,000
| Closed | -$2.28M |
|
|
CBPO
86
DELISTED
China Biologic Products Holdings, Inc.
CBPO
| – | – |
-100,000
| Closed | -$10M |
|
Similar funds
AHC
FFS
GIP
SLF
BFPW
MSA
MAM
GF
Cormorant Asset Management's Q2 2017 Portfolio in Review
As of Q2 2017, Cormorant Asset Management held 86 positions worth $603M, down 12% from $689M the previous quarter. Its ten largest holdings account for 45% of the portfolio.
Cormorant Asset Management withdrew a net $61M in Q2 2017, closing 15 positions and reducing 19 holdings. Its most notable exit was Corbus Pharmaceuticals, an estimated $13.9M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Miscellaneous.
Against the trend, Cormorant Asset Management opened a new position in bluebird bio worth $28.9M.
- Cormorant Asset Management's largest Q2 2017 buy was bluebird bio: 21,230 shares worth $28.9M.
- Cormorant Asset Management added most to Portola Pharmaceuticals, Inc. in Q2 2017, an estimated $12M increase.
- Cormorant Asset Management's biggest Q2 2017 reduction was Theravance Biopharma, cutting an estimated $18.3M.
- Cormorant Asset Management fully exited Corbus Pharmaceuticals in Q2 2017, selling an estimated $13.9M.
- Cormorant Asset Management's ten largest holdings make up 45% of its $603M portfolio in Q2 2017.
- Cormorant Asset Management opened 11 new positions and closed 15 in Q2 2017.
- Cormorant Asset Management's portfolio value fell 12% quarter-over-quarter to $603M.
Based on Cormorant Asset Management's 13F filing for Q2 2017, filed 14 Aug 2017.